[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tarsus Pharmaceuticals, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100636161","phase-2-a-study-to-evaluate-safety-and-efficacy-of-tp-05-in-healthy-participants-with-tick-exposure-100636161",false,"NCT07562087","A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TP-05 in Healthy Participants at High Risk of Tick Exposure","Inclusion Criteria:\n\n* Overtly healthy adult participants aged 18 to 70 years\n* Able to provide written informed consent\n* Willing and able to comply with study procedures\n* At high risk of exposure to ticks\n* Contraceptive use by men and women consistent with local regulations\n\nExclusion Criteria:\n\n* Prior exposure to TP05 or any isooxazoline in the last 12 months\n* Known hypersensitivity to TP05 or related compounds\n* Clinically significant medical conditions that may interfere with study participation\n* Use of investigational products within 30 days prior to screening.\n* Received previous vaccination against Lyme borreliosis, including investigational vaccines intended to prevent Lyme borreliosis\n* Receiving long-term antibiotic therapy\n* Received active or passive immunization within 4 weeks prior to Day\n* Pregnant or breastfeeding individuals",true,"ALL","18 Years","70 Years",{"count":21,"type":22},700,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.",[28],"Lyme Disease",[28,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Lyme Borreliosis","Lyme","Borrelia","Preventative Therapeutic","Prophylaxis","Healthy Volunteers","Randomized Controlled Trial","Gram-Negative Bacterial Infections","Bacterial Infections","Bacterial Infections and Mycoses","Infections","Borrelia Infections","Spirochaetales Infections","Tick-Borne Diseases","Vector Borne Diseases","RECRUITING","2026-05-18",{"date":48,"type":49},"2026-05-20","ACTUAL",{"date":51,"type":49},"2026-03-09",{"date":53,"type":22},"2027-12",{"name":55,"class":56},"Tarsus Pharmaceuticals, Inc.","INDUSTRY",19,""]